Login
Companies $ENGN
$1.95 +$0.06 (3.17%) After hours
enGene Therapeutics Inc. logo

enGene Therapeutics Inc.

engene.com

What Do They Do?

Develops non-viral genetic medicines, led by a bladder-instillable therapy for bladder cancer patients, and is exploring treatments for other cancers and diseases.

Who Are Their Customers?

Its lead medicine is being developed for patients with bladder cancer whose disease has not responded to BCG treatment; the company plans to sell it itself in the United States if approved and may partner outside the United States.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Jul 31, 2026
Net income
▼ −12% (Loss)
vs −$29M in Q3 FY2025
  • Nov 11, 2026 Reported updated pivotal-trial results and FDA alignment on its planned application The company said it plans to begin submitting its application by year end.
  • Jul 15, 2026 Chairman resigned and another board member became chairman
  • Jun 13, 2026 Cut its workforce by about half and planned executive departures The company said it would focus on its pivotal trial, a surfactant cohort, planned regulatory work and pre-commercial activities.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support